Ratings by Wolfe Research (Andy Chen)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/10/2026 | Kymera Therapeutics | KYMR | Upgrade | Outperform (Peerperform) |
115.43 (117.00) |
1.36% | Details | |
| 8/31/2026 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Outperform (N/A) |
43.60 (37.98) |
-12.89% | Details | |
| 8/10/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2026 | Madrigal Pharmaceuticals | MDGL | Upgrade | Outperform (Peerperform) |
482.00 (533.12) |
10.61% | Details | |
| 7/28/2026 | Spyre | SYRE | Downgrade | Peerperform (Outperform) |
100.04 (88.71) |
-11.33% | Details | |
| 7/16/2026 | Ionis Pharmaceuticals | IONS | Downgrade | Peerperform (Outperform) |
54.93 (55.65) |
1.31% | Details | |
| 7/16/2026 | Intellia Therapeutics | NTLA | Downgrade | Underperform (Peerperform) |
13.30 (11.93) |
-10.3% | Details | |
| 7/8/2026 | Sarepta Therapeutics | SRPT | Upgrade | Outperform (Peerperform) |
19.79 (20.52) |
3.69% | Details | |
| 6/10/2026 | Dianthus Therapeutics | DNTH | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2026 | Vera Therapeutics | VERA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2026 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2026 | Pharvaris B.V. | PHVS | New Coverage | Outperform (N/A) |
27.84 (37.51) |
34.73% | Details | |
| 4/8/2026 | Avalo Therapeutics Inc. | AVTX | New Coverage | Outperform (N/A) |
15.92 (17.18) |
7.91% | Details | |
| 4/8/2026 | Dianthus Therapeutics | DNTH | New Coverage | Outperform (N/A) |
86.20 (103.28) |
19.81% | Details | |
| 4/8/2026 | Palisade Bio Inc. | PALI | New Coverage | Outperform (N/A) |
1.91 (2.01) |
5.24% | Details | |
| 4/1/2026 | Madrigal Pharmaceuticals | MDGL | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/31/2026 | Apellis Pharmaceuticals | APLS | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/31/2026 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/25/2026 | Sarepta Therapeutics | SRPT | Maintain | Peerperform (N/A) |
|
Details | ||
| 3/25/2026 | Ionis Pharmaceuticals | IONS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2026 | Celldex Therapeutics | CLDX | Upgrade | Outperform (Peerperform) |
30.90 (38.10) |
23.3% | Details | |
| 3/23/2026 | Moonlake Immunotherapeutics | MLTX | Upgrade | Outperform (Peerperform) |
16.27 (13.18) |
-18.99% | Details | |
| 3/10/2026 | Vera Therapeutics | VERA | Upgrade | Outperform (Peerperform) |
38.97 (33.60) |
-13.78% | Details | |
| 3/9/2026 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2026 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | Apogee Therapeutics Inc | APGE | New Coverage | Peerperform (N/A) |
77.51 (135.07) |
74.26% | Details | |
| 1/6/2026 | Spyre | SYRE | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Oruka Therapeutics | ORKA | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Vertex | VRTX | Upgrade | Outperform (Peerperform) |
448.80 (514.56) |
14.65% | Details | |
| 1/6/2026 | Kymera Therapeutics | KYMR | Downgrade | Peerperform (Outperform) |
72.41 (115.43) |
59.41% | Details | |
| 1/6/2026 | Madrigal Pharmaceuticals | MDGL | Downgrade | Peerperform (Outperform) |
588.40 (482.00) |
-18.08% | Details | |
| 1/6/2026 | Alnylam Pharmaceuticals | IMVT | Upgrade | Outperform (Peerperform) |
397.83 (38.10) |
-90.42% | Details | |
| 12/18/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/24/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 11/24/2025 | argenx SE | ARGX | Downgrade | Peerperform (Outperform) |
918.92 (984.04) |
7.09% | Details | |
| 11/13/2025 | Madrigal Pharmaceuticals | MDGL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | Intellia Therapeutics | NTLA | Downgrade | Peerperform (Outperform) |
9.73 (13.30) |
36.69% | Details | |
| 10/29/2025 | Avidity Biosciences | RNA | Downgrade | Peerperform (Outperform) |
70.00 (10.35) |
-85.21% | Details | |
| 10/10/2025 | Akero Therapeutics | AKRO | Downgrade | Peerperform (Outperform) |
46.49 (54.74) |
17.75% | Details | |
| 9/24/2025 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 9/19/2025 | 89bio Inc. | ETNB | Downgrade | Peerperform (Outperform) |
8.08 (14.84) |
83.66% | Details | |
| 9/11/2025 | Kymera Therapeutics | KYMR | Maintain | Outperform (N/A) |
|
Details | ||
| 8/14/2025 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2025 | Alnylam Pharmaceuticals | ALNY | Upgrade | Peerperform (Underperform) |
401.80 (247.51) |
-38.4% | Details | |
| 8/4/2025 | Vera Therapeutics | VERA | Downgrade | Peerperform (Outperform) |
20.95 (38.97) |
86.01% | Details | |
| 7/1/2025 | Verona Pharma | VRNA | New Coverage | Outperform (N/A) |
93.82 (106.91) |
13.95% | Details | |
| 6/17/2025 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
39.78 (72.50) |
82.25% | Details | |
| 6/17/2025 | Sarepta Therapeutics | SRPT | New Coverage | Peerperform (N/A) |
36.18 (20.52) |
-43.28% | Details | |
| 6/17/2025 | Avidity Biosciences | RNA | New Coverage | Outperform (N/A) |
31.37 (70.00) |
123.14% | Details | |
| 6/3/2025 | Blueprint Medicines | BPMC | Downgrade | Peerperform (Outperform) |
101.35 (129.46) |
27.74% | Details | |
| 5/21/2025 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2025 | Moonlake Immunotherapeutics | MLTX | Upgrade | Outperform (Peerperform) |
37.62 (13.18) |
-64.97% | Details | |
| 5/7/2025 | Vertex | VRTX | Downgrade | Peerperform (Outperform) |
500.19 (514.56) |
2.87% | Details | |
| 4/21/2025 | Intellia Therapeutics | NTLA | Upgrade | Outperform (Peerperform) |
7.23 (9.73) |
34.58% | Details | |
| 3/18/2025 | Spyre | SYRE | New Coverage | Outperform (N/A) |
18.04 (100.04) |
454.55% | Details | |
| 3/18/2025 | Blueprint Medicines | BPMC | New Coverage | Outperform (N/A) |
89.58 (129.46) |
44.52% | Details | |
| 2/4/2025 | Zenas Biopharma | ZBIO | New Coverage | Outperform (N/A) |
8.02 (31.10) |
287.78% | Details | |
| 2/4/2025 | Vera Therapeutics | VERA | New Coverage | Outperform (N/A) |
37.28 (33.60) |
-9.87% | Details | |
| 2/4/2025 | Crinetics | CRNX | New Coverage | Peerperform (N/A) |
40.30 (84.95) |
110.79% | Details | |
| 2/4/2025 | Oruka Therapeutics | ORKA | New Coverage | Outperform (N/A) |
13.45 (91.65) |
581.41% | Details | |
| 2/4/2025 | 89bio Inc. | ETNB | New Coverage | Outperform (N/A) |
9.60 (8.08) |
-15.83% | Details | |
| 2/4/2025 | AnaptysBio | ANAB | New Coverage | Outperform (N/A) |
17.93 (55.16) |
207.64% | Details | |
| 1/3/2025 | Immunovant | IMVT | Downgrade | Peerperform (Outperform) |
25.19 (38.10) |
51.25% | Details | |
| 11/12/2024 | argenx SE | ARGX | Upgrade | Outperform (Peerperform) |
596.00 (918.92) |
54.18% | Details | |
| 11/12/2024 | Alnylam Pharmaceuticals | ALNY | Downgrade | Underperform (Peerperform) |
277.43 (247.51) |
-10.78% | Details | |
| 10/1/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2024 | Incyte | INCY | New Coverage | Outperform (N/A) |
65.83 (123.28) |
87.27% | Details | |
| 9/27/2024 | Celldex Therapeutics | CLDX | Downgrade | Peerperform (Outperform) |
36.02 (38.10) |
5.77% | Details | |
| 9/3/2024 | Alnylam Pharmaceuticals | ALNY | Maintain | Peerperform (N/A) |
|
Details | ||
| 8/26/2024 | Kymera Therapeutics | KYMR | Upgrade | Outperform (Peerperform) |
47.78 (117.00) |
144.87% | Details | |
| 8/26/2024 | Moonlake Immunotherapeutics | MLTX | Downgrade | Peerperform (Outperform) |
49.77 (37.62) |
-24.41% | Details | |
| 8/5/2024 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 6/11/2024 | Celldex Therapeutics | CLDX | New Coverage | Outperform (N/A) |
35.28 (38.10) |
7.99% | Details | |
| 6/11/2024 | Viridian Therapeutic | VRDN | New Coverage | Outperform (N/A) |
12.17 (22.29) |
83.16% | Details | |
| 6/11/2024 | Akero Therapeutics | AKRO | New Coverage | Outperform (N/A) |
23.02 (46.49) |
101.95% | Details | |
| 6/11/2024 | Madrigal Pharmaceuticals | MDGL | New Coverage | Outperform (N/A) |
244.34 (533.12) |
118.19% | Details | |
| 5/29/2024 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2024 | Rapt Therapeutics | RAPT | Downgrade | Peerperform (Outperform) |
4.40 (58.02) |
1218.64% | Details | |
| 4/11/2024 | Alpine Immune Sciences | ALPN | Downgrade | Peerperform (Outperform) |
47.04 (64.97) |
38.12% | Details | |
| 4/10/2024 | Ionis Pharmaceuticals | IONS | Upgrade | Outperform (Peerperform) |
42.24 (54.93) |
30.04% | Details | |
| 3/20/2024 | Alpine Immune Sciences | ALPN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/15/2024 | Moonlake Immunotherapeutics | MLTX | New Coverage | Outperform (N/A) |
62.99 (13.18) |
-79.08% | Details | |
| 2/15/2024 | CRISPR Therapeutics | CRSP | New Coverage | Peerperform (N/A) |
72.78 (52.26) |
-28.19% | Details | |
| 2/15/2024 | Kymera Therapeutics | KYMR | New Coverage | Peerperform (N/A) |
35.03 (117.00) |
234% | Details | |
| 2/15/2024 | Insmed | INSM | New Coverage | Outperform (N/A) |
26.60 (127.28) |
378.5% | Details | |
| 2/15/2024 | Alpine Immune Sciences | ALPN | New Coverage | Outperform (N/A) |
28.77 (64.97) |
125.83% | Details | |
| 2/15/2024 | Rapt Therapeutics | RAPT | New Coverage | Outperform (N/A) |
24.99 (58.02) |
132.17% | Details | |
| 2/15/2024 | argenx SE | ARGX | New Coverage | Peerperform (N/A) |
386.83 (984.04) |
154.39% | Details | |
| 2/15/2024 | Vertex | VRTX | New Coverage | Outperform (N/A) |
416.04 (500.19) |
20.23% | Details | |
| 2/15/2024 | Intellia Therapeutics | NTLA | New Coverage | Peerperform (N/A) |
26.45 (11.93) |
-54.9% | Details | |
| 2/15/2024 | Roivant Sciences | ROIV | New Coverage | Outperform (N/A) |
10.80 (40.94) |
279.07% | Details | |
| 2/15/2024 | Immunovant | IMVT | New Coverage | Outperform (N/A) |
36.92 (38.10) |
3.2% | Details | |
| 2/14/2024 | Alnylam Pharmaceuticals | ALNY | New Coverage | Peerperform (N/A) |
162.00 (247.51) |
52.78% | Details |
